Ipilimumab augments antitumor activity of bispecific antibody-armed T cells

BACKGROUND: Ipilimumab is an antagonistic monoclonal antibody against cytotoxic T-lymphocyte antigen-4 (CTLA-4) that enhances antitumor immunity by inhibiting immunosuppressive activity of regulatory T cells (Treg). In this study, we investigated whether inhibiting Treg activity with ipilimumab duri...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yano, Hiroshi, Thakur, Archana, Tomaszewski, Elyse N, Choi, Minsig, Deol, Abhinav, Lum, Lawrence G
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4105782/
https://ncbi.nlm.nih.gov/pubmed/25008236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-191
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares